Merck 3Q profit plunges 35 pct. on generic competition, lower sales of top seller, charges

Merck & Co. says its third-quarter profit plunged 35 per cent because of competition from generic drugs, lower sales of its top-selling medicine, and restructuring and acquisition charges.

The world’s second-biggest drugmaker says net income was $1.12 billion, or 38 cents per share, down from $1.73 billion, or 56 cents per share, a year earlier.

The maker of Type 2 diabetes pill Januvia says that excluding the one-time items, net income would have been $2.73 billion, or 92 cents per share. Analysts surveyed by FactSet were expecting 88 cents per share.

Revenue totalled $11.03 billion, down 4 per cent. That missed expectations for $11.13 billion in revenue.

The company lowered its 2013 profit forecast to $1.61 to $1.79 per share, from its July forecast of $1.84 to $2.05.

News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day.